Benzoxazolinone derivatives and preparation methods and uses thereof
By designing and synthesizing new benzooxazolinone derivatives, the NF-κB pathway was inhibited, and the problem of major side effects of existing anti-inflammatory drugs was solved, achieving significant anti-inflammatory effects and fewer side effects.
Patent Information
- Application Number
- CN202211450288.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-19
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2042-11-19
AI Technical Summary
The clinical application of existing anti-inflammatory drugs is restricted due to gastrointestinal side effects and potential cardiovascular adverse reactions, and it is urgent to develop new drugs with anti-inflammatory effects and fewer side effects.
A series of novel benzooxazolinone derivatives with good anti-inflammatory activity and small side effects were designed and synthesized, which reduces iNOS expression by inhibiting the NF-κB pathway, reduces NO release, and reduces the proinflammatory cytokine TNF- Expression of α, IL-1β and IL-6.
Significantly better anti-inflammatory activity was achieved, reducing NO release and expression of pro-inflammatory cytokines, showing fewer side effects.
Smart Images

Figure CN115677610B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical chemistry, and specifically relates to a benzoxazolinone derivative and a preparation method and use thereof. Background Art
[0002] Inflammation is a defensive response of the body to external stimuli or cell damage, involving the participation of many inflammatory mediators and immune cells. Appropriate inflammatory response is essential for eliminating cell damage and repairing damaged tissues. However, excessive inflammatory response can be involved in the occurrence and development of many diseases, such as autoimmune or autoinflammatory diseases, neurodegenerative diseases and cancer [Dinarello C A. Anti-inflammatory agents: present and future [J]. Cell. 2010, 140 (6): 935-950.].
[0003] At present, the clinical application of nonsteroidal anti-inflammatory drugs is limited due to gastrointestinal side effects and potential cardiovascular adverse reactions. Therefore, it is urgent to develop new drugs or therapies with anti-inflammatory effects and fewer side effects. Finding new drugs from natural products with fewer side effects has always been one of the drug development strategies. Designing high-efficiency and low-toxic candidate drugs using active small molecules of traditional Chinese medicine as lead compounds has become a research hotspot for anti-inflammatory drugs [Li Z, Xu S, Liu P. Salvia miltiorrhiza Burge (Danshen): a golden herbal medicine in cardiovascular therapeutics [J]. Acta. Pharmacol. Sin. 2018, 39 (5): 802-824.].
[0004] Benzoxazoles are widely present in nature as plant secondary metabolites. Their derivatives have multiple pharmacological effects such as anti-inflammatory, anti-cancer, antibacterial and anti-HIV, and have broad application prospects [Xi KW, Yeong K YA patent review on the current developments of benzoxazoles in drug discovery [J]. Chem. Med. Chem. 2021, 16: 3237-3262.]. Yiyisu is a traditional Chinese medicine active small molecule containing a benzoxazole skeleton and has multiple biological activities. Studies have shown that coixol can effectively reduce the expression of IL-1β, IL-6, tumor necrosis factor-α (TNF-α) and nitric oxide (NO) by inhibiting the nuclear factor-κB (NF-κB) signaling pathway, thereby exerting an anti-inflammatory effect [Hu Y, Zhou Q, Liu T, et al. Coixol suppresses NF-κB, MAPK pathways and NLRP3inflammasome activation in lipopolysaccharide-induced RAW 264.7 cells[J]. Molecules. 2020, 25(4): 894-904.].
[0005]
[0006] Ipomoea batatas structure
[0007] The present invention designs and synthesizes a series of novel benzoxazolinone derivatives with good anti-inflammatory activity and small side effects on the basis of coixol. Summary of the invention
[0008] In order to overcome the deficiencies of the prior art, the present invention provides a compound having formula (I) as shown in
[0009]
[0010] or tautomers, cis-trans isomers, isotope-labeled substances and pharmaceutically acceptable salts thereof, wherein X1, X2, R1, n and m are as defined herein.
[0011] On the other hand, the present invention provides a pharmaceutical composition comprising a compound represented by formula (I) or its tautomers, cis-trans isomers, isotope-labeled substances and pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier.
[0012] On the other hand, the present invention provides the use of the compound represented by formula (I) or its tautomers, cis-trans isomers, isotope-labeled substances and pharmaceutically acceptable salts and / or pharmaceutical compositions containing the same in the preparation of drugs for preventing and / or treating inflammation-related diseases.
[0013] Beneficial effects: Compared with the prior art, the compounds of the present invention can effectively reduce the expression of iNOS, reduce the release of NO, and reduce the expression of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 by inhibiting the NF-κB pathway, showing significantly better anti-inflammatory activity. DETAILED DESCRIPTION
[0014] definition
[0015] As used in this specification, the following words and phrases are generally intended to have the meanings set forth below, unless the context in which they are used indicates otherwise.
[0016] As used herein, the term "alkyl" refers to a monovalent group of a straight or branched saturated hydrocarbon chain having 1 to 20 carbon atoms, more typically 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, 1-propyl (n-propyl), 2-propyl (isopropyl), 1-butyl (n-butyl), 2-methyl-1-propyl (isobutyl), 2-butyl (sec-butyl), 2-methyl-2-propyl (tert-butyl), 1-pentyl (n-pentyl), 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, 1-heptyl, 1-octyl, 1-nonyl, 1-decyl, and the like.
[0017] As used herein, the term "alkenyl" refers to a linear or branched unsaturated hydrocarbon chain monovalent group having 2 to 20 carbon atoms (more typically 2 to 10 carbon atoms, 2 to 8 carbon atoms, or 2 to 6 carbon atoms) and having carbon-carbon double bonds (e.g., 1, 2 or 3 carbon-carbon double bonds). The term is exemplified by groups such as vinyl (i.e., -CH=CH2), propen-1-yl (i.e., -CH=CHCH3), propen-3-yl (or allyl, i.e., -CH2CH=CH2), propen-2-yl (i.e., -C(CH3)=CH2), butadienyl (including 1,2-butadienyl and 1,3-butadienyl), and the like.
[0018] As used herein, the term "alkynyl" refers to a linear or branched unsaturated hydrocarbon chain monovalent group having 2 to 20 carbon atoms (more typically 2 to 10 carbon atoms, 2 to 8 carbon atoms, or 2 to 6 carbon atoms) and having carbon-carbon triple bonds (e.g., 1, 2 or 3 carbon-carbon triple bonds). The term is exemplified by groups such as ethynyl (i.e., -C≡CH), propargyl (i.e., -CH2C≡CH), propynyl (i.e., -C≡CCH3), etc.
[0019] As used herein, the term "aryl" refers to an aromatic carbocyclic group of 6 to 14 carbon atoms (more typically 6 to 10 carbon atoms, or 6 carbon atoms) having a single ring (e.g., phenyl) or multiple rings (e.g., biphenyl) or multiple condensed (fused) rings (e.g., naphthyl, fluorenyl, and anthracenyl). The term is exemplified by groups such as phenyl, fluorenyl, naphthyl, anthracenyl, 1,2,3,4-tetrahydronaphthalene (if the point of attachment is through the aryl group), and the like.
[0020] As used herein, the term "halogen" refers to fluorine, chlorine, bromine and iodine.
[0021] As used herein, the term "alkoxy" refers to an "alkyl-O-" group, wherein alkyl is as defined herein. This term is exemplified by groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, and the like.
[0022] As used herein, the term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a halogen, wherein alkyl is as defined herein. The term is exemplified by the groups trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2,2-trifluoroethyl, 1,1,-difluoroethyl, etc.
[0023] As used herein, the term "carbocycle", "carbocyclic radical" refers to a monocyclic saturated or partially unsaturated group of 3 to 8 members of a monocyclic ring or a plurality of thick (fused) rings or bridged rings or spirocycles having 3 to 14 carbon atoms as ring atoms.Carbocycle or carbocyclic radical can be saturated or partially unsaturated, and can be fused with another saturated, partially unsaturated or aromatic ring, provided that the ring atom connected to the target molecule is not an aromatic carbon.Examples of carbocycle or carbocyclic radical include, but are not limited to cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, etc.
[0024] As used herein, the term "heteroaromatic ring", "heteroaryl" refers to an aromatic ring group containing a monocyclic or multiple condensed (fused) ring (e.g., containing 2 or 3 rings) of 5 to 14 ring atoms in the ring, wherein in addition to carbon atoms, the ring atoms also contain at least one heteroatom selected from oxygen, nitrogen and / or sulfur. If the ring is aromatic, the sulfur and nitrogen atoms can also exist in oxidized form. Multiple condensed (fused) ring heteroaryl is a monocyclic heteroaryl as defined above fused with one or more rings selected from the following to form a multiple condensed ring system: heteroaryl (to form, for example, naphthyridinyl, such as 1,8-naphthyridinyl), heterocyclic (for example, 1,2,3,4-tetrahydronaphthyridinyl, such as 1,2,3,4-tetrahydro-1,8-naphthyridinyl), carbocyclic (to form, for example, 5,6,7,8-tetrahydroquinolinyl) and aryl (to form, for example, indazolyl). Such multiple fused ring systems can be optionally substituted with one or more (e.g., 1, 2, 3, or 4) oxo groups on the carbocyclic or heterocyclic portions of the fused rings. When valence requirements permit, the rings of the multiple fused ring systems can be interconnected by fusion, spirocyclic, and bridging bonds. It should be understood that the individual rings of the multiple fused ring systems can be connected to each other in any order. It should also be understood that the attachment point of the multiple fused ring system can be at any position of the multiple fused ring system, including heteroaryl, heterocyclic, aryl, or carbocyclic portions of the multiple fused system. It should also be understood that the attachment point of the heteroaryl group can be on any suitable atom of the heteroaryl group, including carbon atoms and heteroatoms (e.g., nitrogen). Exemplary heteroaryl groups include, but are not limited to, pyridinyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furanyl, oxadiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalinyl, quinazolinyl, 5,6,7,8-tetrahydroisoquinolinyl, benzofuranyl, benzo[d][1,3]dioxolyl, benzimidazolyl, thiaindenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, 4,5,6,7-tetrahydro-1H-indazolyl, and 3b,4,4a,5-tetrahydro-1H-cyclopropane[3,4]cyclopenta[1,2-c]pyrazolyl.
[0025] As used herein, the terms "heterocycle", "heterocyclyl" and "heterocyclic group" refer to a monoradical saturated or partially unsaturated group having a 3- to 8-membered monocyclic ring or multiple condensed (fused) rings or bridged rings having 3 to 14 ring atoms in the ring, wherein in addition to carbon atoms, the ring atoms also contain at least one heteroatom selected from oxygen, nitrogen and / or sulfur. Examples of heterocyclyl groups include, but are not limited to, aziridine, azetidine, tetrahydropyrrole, piperidine, azepane, aziroxane, oxetane, tetrahydrofuran, tetrahydropyran, oxepane, oxocane, thiirane, thietane, tetrahydrothiophene, tetrahydrothiopyran, thiepane, thiocane, tetrahydroimidazole, tetrahydropyrazole, tetrahydrooxazole, tetrahydroisoxazole, tetrahydrothiazole, tetrahydroisothiazole, piperazine, morpholine, dioxane, thioxane, dithiane, dihydropyridyl, 4,5,6,7-tetrahydro-1H-benzo[d]imidazole, 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine, and the like.
[0026] As used herein, the term "therapeutically effective amount" refers to an amount sufficient to affect treatment as defined below when administered to a mammal in need of such treatment. The therapeutically effective amount will vary with the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the mode of administration, etc., and can be readily determined by one of ordinary skill in the art.
[0027] As used herein, the term "cis-trans isomers" refers to isomers that appear in a compound molecule due to restrictions on free rotation, such as C=C double bonds, C=N double bonds, C=S double bonds, N=N double bonds or alicyclic rings, which cause different arrangements of various groups in space. Organic molecules containing such isomers, such as olefins, azo compounds, alicyclic hydrocarbons, etc., are regarded as cis-trans isomers and are named according to the "cis-trans isomer nomenclature" or "ZE nomenclature".
[0028] As used herein, the term "tautomer" refers to the coexistence of two (or more) compounds that differ only in the position and electron distribution of one (or more) mobile atoms, such as keto-enol tautomers.
[0029] As used herein, the term "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness and properties of a given compound and are not biologically or otherwise undesirable. Pharmaceutically acceptable salts can be acid addition salts and / or base addition salts. Acid addition salts can be prepared from inorganic acids and organic acids. Salts derived from inorganic acids include hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, carbonates, bisulfates, hydrogenphosphates, dihydrogenphosphates, bicarbonates, etc.; salts derived from organic acids include formates, acetates, propionates, glycolates, pyruvates, oxalates, malates, malonates, succinates, maleates, fumarates, tartrates, citrates, benzoates, cinnamates, mandelates, methanesulfonates, ethanesulfonates, p-toluenesulfonates, salicylates, lactates, nicotinates, lauryl sulfates, naphthylsulfonates, camphorsulfonates, gluconates, glucuronates, oleates, palmitates, stearates, pamoates, trifluoroacetates, etc. Base addition salts can be formed with inorganic or organic bases. Salts derived from inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, lithium, barium, aluminum salts and the like; salts derived from organic bases include salts formed with various primary, secondary and tertiary amines, for example, ethylamine, diethylamine, n-propylamine, isopropylamine, diethanolamine, meglumine, lysine, piperazine, piperidine, morpholine, tromethamine, choline and the like.
[0030] As used herein, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the mammal to be treated therewith.
[0031] Any formula or structure given herein, including Formula I or any formula disclosed herein, is also intended to represent unlabeled forms of the compounds as well as isotopically labeled forms. These isotopically labeled forms of compounds may also be referred to as "isotopically labeled" or "isotopically enriched analogs." Isotopically labeled compounds have structures depicted herein except that one or more atoms are replaced by atoms having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, such as, but not limited to, 2 H (deuterium, D), 3 H (tritium), 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 36Cl, 123 I and 125 I. Various isotope-labeled compounds of the present invention, for example, compounds into which a radioactive isotope (e.g. 3 H. 13 C and 14 C). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced with deuterium.
[0032] Compound
[0033] In one embodiment, the present invention provides a compound represented by formula (I)
[0034]
[0035] or its tautomers, cis-trans isomers, isotope-labeled substances and pharmaceutically acceptable salts, wherein
[0036] X1 is selected from CH2, NH, O or S;
[0037] n is an integer between 1 and 4;
[0038] Each R1 is independently selected from hydrogen, C1-C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C1-C 20 Halogenated alkyl, C1-C 20 Alkoxy, C1-C 20 Alkanoyl, C1-C 20 Alkanoyloxy, halogen, hydroxy, cyano, nitro, carboxyl;
[0039] X2 is selected from C6-C 14 aryl, 5- to 14-membered heteroaryl, 3- to 14-membered heterocyclic group or C3-C 14 Carbocyclic group, which is optionally substituted by one or more groups selected from the group consisting of halogen, oxo, C1-C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C1-C 20 Halogenated alkyl, C1-C 20 Alkoxy, C1-C 20 Alkanoyl, C1-C 20 Alkanoyloxy, C1-C 20 Alkoxycarbonyl, C1-C 20 Alkoxycarbonyloxy, hydroxy, cyano, nitro, carboxyl;
[0040] m is 0 or 1;
[0041] The condition is: when m is 0, at least one R1 is C1-C 20 Alkoxy, and does not contain the following compounds:
[0042]
[0043] In one embodiment, in the compound of formula (I) provided by the present invention, X1 is selected from CH2, NH, O or S; preferably, X1 is selected from NH, O or S; more preferably, X1 is selected from O or S; most preferably, X1 is selected from O.
[0044] In one embodiment, in the compound of formula (I) provided by the present invention, n is an integer between 1 and 4; preferably, n is 1 or 2 or 3; more preferably, n is 1 or 2; most preferably, n is 1.
[0045] In one embodiment, in the compound of formula (I) provided by the present invention, each R1 is independently selected from hydrogen, C1-C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C1-C 20 Halogenated alkyl, C1-C 20 Alkoxy, C1-C 20 Alkanoyl, C1-C 20 Alkanoyloxy, halogen, hydroxyl, cyano, nitro, carboxyl; preferably, each R1 is independently selected from hydrogen, C1-C 20 Alkyl, C1-C 20 Halogenated alkyl, C1-C 20 Alkoxy, halogen, hydroxy, cyano, nitro, carboxyl; More preferably, each R1 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, halogen; Most preferably, each R1 is independently selected from hydrogen, methyl, methoxy, trifluoromethyl, halogen.
[0046] In one embodiment, in the compound represented by formula (I) provided by the present invention, X2 is selected from C6-C 14 aryl, 5- to 14-membered heteroaryl, 3- to 14-membered heterocyclic group or C3-C 14 Carbocyclic group, which is optionally substituted by one or more groups selected from the group consisting of halogen, oxo, C1-C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C1-C 20 Halogenated alkyl, C1-C 20 Alkoxy, C1-C 20 Alkanoyl, C1-C 20 Alkanoyloxy, C1-C 20Alkoxycarbonyl, C1-C 20 Alkoxycarbonyloxy, hydroxyl, cyano, nitro, carboxyl; preferably, X2 is selected from C6-C 10 aryl, 5- to 10-membered heteroaryl, 3- to 8-membered heterocyclyl or C3-C8 carbocyclyl, which is optionally substituted by one or more groups selected from the following: halogen, C1-C8 20 Alkyl, C1-C 20 Halogenated alkyl, C1-C 20 Alkoxy, C1-C 20 Alkanoyl, C1-C 20 Alkanoyloxy, C1-C 20 Alkoxycarbonyl, C1-C 20 Alkoxycarbonyloxy, hydroxyl, cyano, nitro, carboxyl; More preferably, X2 is selected from C6-C 10aryl, 5 to 10 membered heteroaryl, 3 to 8 membered heterocyclic radical or C3-C8 carbocyclic radical, which is optionally substituted by one or more groups selected from the following: halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxycarbonyloxy, hydroxyl, cyano, nitro, carboxyl; further preferably, X2 is selected from phenyl, naphthyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinoline quinolinyl, isoquinolinyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalinyl, quinazolinyl, 5,6,7,8-tetrahydroisoquinolinyl, benzofuranyl, benzo[d][1,3]dioxolyl, benzimidazolyl, thiaindenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, 4,5,6,7-tetrahydro-1H-indazolyl and 3b,4,4a,5-tetrahydro-1H-cyclopropane[3,4]cyclopentane[1,2-c]pyrazolyl, aziridine ring, azetidine ring, tetrahydropyrrole ring, piperidine ring, azepane ring, azirocyl ring, oxirane ring, oxadiazine ring heterocyclobutane ring, tetrahydrofuran ring, tetrahydropyran ring, oxepane ring, oxoctane ring, thiirane ring, thietane ring, tetrahydrothiophene ring, tetrahydrothiopyran ring, thiepane ring, thioctane ring, tetrahydroimidazole ring, tetrahydropyrazole ring, tetrahydrooxazole ring, tetrahydroisoxazole ring, tetrahydrothiazole ring, tetrahydroisothiazole ring, piperazine ring, morpholine ring, dioxane ring, thioxane ring, dithiane ring, dihydropyridyl, 4,5,6,7-tetrahydro-1H-benzo[d]imidazole, 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclobutene, cyclopentene, cyclohexene, cyclo heptene, cyclopentadiene, which are optionally substituted by one or more groups selected from the following: halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxycarbonyloxy, hydroxyl, cyano, nitro, carboxyl; further preferably, X2 is selected from phenyl, furanyl, thienyl, benzo[d][1,3]dioxole, benzofuranyl, pyridyl, which are optionally substituted by one or more groups selected from the following: halogen, methyl, trifluoromethyl, methoxy, cyano, nitro; most preferably, X2 is selected from phenyl, It is optionally substituted by one or more groups selected from the group consisting of halogen, methyl, trifluoromethyl, methoxy, cyano, nitro.
[0047] In one embodiment, the present invention provides a compound represented by formula (II):
[0048]
[0049] or tautomers, cis-trans isomers, isotope-labeled substances and pharmaceutically acceptable salts thereof, wherein X1, X2, R1 and n are as defined herein.
[0050] In one embodiment, the present invention provides a compound represented by formula (III):
[0051]
[0052] or tautomers, cis-trans isomers, isotope-labeled substances and pharmaceutically acceptable salts thereof, wherein X1, X2 and R1 are as defined herein.
[0053] In one embodiment, the present invention provides a compound represented by formula (IV):
[0054]
[0055] or its tautomers, cis-trans isomers, isotope-labeled substances and pharmaceutically acceptable salts, wherein X1, X2 and R1 are as defined herein, provided that: R1 is C1-C 20 Alkoxy, and does not contain the following compounds:
[0056]
[0057] In a specific embodiment, the compound represented by formula (II) of the present invention is a compound:
[0058]
[0059] or tautomers, cis-trans isomers, isotope-labeled substances and pharmaceutically acceptable salts thereof, wherein X1, X2, R1 and n are as defined herein.
[0060] In a specific embodiment, the compound represented by formula (III) of the present invention is a compound:
[0061]
[0062] or tautomers, cis-trans isomers, isotope-labeled substances and pharmaceutically acceptable salts thereof, wherein X1, X2 and R1 are as defined herein.
[0063] In a specific embodiment, the compounds of the present invention include but are not limited to the following compounds:
[0064] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-phenyl)acrylamide;
[0065] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-fluorophenyl)acrylamide;
[0066] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-chlorophenyl)acrylamide;
[0067] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-methylphenyl)acrylamide;
[0068] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-trifluoromethylphenyl)acrylamide;
[0069] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-hydroxyphenyl)acrylamide;
[0070] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide;
[0071] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-methoxyphenyl)acrylamide;
[0072] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4-dimethoxyphenyl)acrylamide;
[0073] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide;
[0074] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-methoxyphenyl)acrylamide;
[0075] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3-methoxyphenyl)acrylamide;
[0076] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-chlorophenyl)acrylamide;
[0077] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3-chlorophenyl)acrylamide;
[0078] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-cyanophenyl)acrylamide;
[0079] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-pyridyl)acrylamide;
[0080] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(1,3-benzodiazol-5-yl)acrylamide;
[0081] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-thienyl)acrylamide;
[0082] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-furyl)acrylamide;
[0083] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3-furyl)acrylamide;
[0084] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(5-methyl-2-furyl)acrylamide;
[0085] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(5-bromo-2-furyl)acrylamide;
[0086] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(1-benzofuran-2-yl)acrylamide;
[0087] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(5-nitro-2-furyl)acrylamide;
[0088] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-2-benzofuranamide;
[0089] (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-2-furanamide;
[0090] (E)-N-(2-(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-furyl)acrylamide;
[0091] (E)-N-(2-(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide;
[0092] (E)-N-(2-(6-bromo-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-furyl)acrylamide;
[0093] (E)-N-(2-(6-bromo-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide;
[0094] or its tautomers, cis-trans isomers, isotope-labeled substances, and pharmaceutically acceptable salts.
[0095] Pharmaceutical compositions and administration
[0096] The pharmaceutical composition provided by the present invention comprises the compound of the present invention or its stereoisomer, tautomer, solvate, prodrug, isotope label, pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are known to those skilled in the art, including diluents, lubricants, disintegrants, adhesives, buffers, preservatives, stabilizers, wetting agents, glidants, emulsifiers, colorants, flavoring agents, sweeteners, etc. According to the different routes of administration of the drug, such as oral administration, parenteral administration and rectal administration, the pharmaceutical composition of the present invention can be made in solid form (including but not limited to tablets, capsules, pills, granules, powders, powders, suppositories) or liquid form (including but not limited to solutions, suspensions, emulsions, tinctures, syrups). When the pharmaceutical composition of the present invention is in solid form, the pharmaceutically acceptable carrier generally includes one or more of the following: a) diluents, such as lactose, glucose, sucrose, mannitol, sorbitol, cellulose, etc.; b) lubricants, such as silicon dioxide, talc, stearic acid, polyethylene glycol, etc.; c) binders, such as magnesium aluminosilicate, gelatinized starch, gelatin, tragacanth gum, methylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, etc.; d) disintegrants, such as starch, alginic acid, agar, corn starch; e) stabilizers, such as antioxidants such as ascorbic acid; f) glidants, such as silicon dioxide; g) flavoring agents, such as mint, methyl salicylate; sweeteners, such as sucrose, saccharin. When the pharmaceutical composition of the present invention is in liquid form, the pharmaceutically acceptable carrier generally includes one or more of the following: a) a diluent, such as water for injection, physiological saline, Ringer's solution, polyethylene glycol, glycerol, propylene glycol, etc.; b) an antioxidant, such as ascorbic acid or sodium bisulfite; c) a buffer, such as acetate, phosphate, etc.
[0097] The effective dose of the compounds of the present invention depends at least on the nature, extent, delivery method and pharmaceutical dosage form of the condition being treated, and will be ultimately determined by the clinician. It can be expected that about 0.0001 to about 100 mg per kilogram of body weight per day; generally about 0.01 to about 10 mg per kilogram of body weight per day; more typically, about 0.01 to about 5 mg per kilogram of body weight per day; most typically about 0.05 to about 0.5 mg per kilogram of body weight per day. For example, the daily candidate dose for an adult of about 70 kg body weight will be in the range of 1 mg to 1000 mg, preferably in the range of 5 mg to 500 mg, and can be administered in the form of a single dose or multiple doses.
[0098] Indications
[0099] The compounds of the present invention have significant anti-inflammatory activity and can be used to treat or prevent inflammation-related diseases, including rheumatoid arthritis, gouty arthritis, osteoarthritis, spondylitis, systemic lupus erythematosus, psoriasis, eczema, subcutaneous inflammation, postpartum inflammation, enteritis, gastritis, inflammatory headache, periarteritis, stroke, ischemia, mental trauma, allergic rhinitis, coronary artery plaque inflammation, bacterial inflammation, viral inflammation, surgical inflammation or gastric ulcer, etc.
[0100] General synthetic method
[0101] Compounds of the present invention can be prepared using methods disclosed herein and their modified approaches and methods well known in the art. Typical embodiments of compounds according to the present invention can be synthesized using the following general reaction schemes. It is apparent from the description herein that corresponding different products can be obtained by replacing reaction raw materials with other materials having similar structures. Reaction raw materials are typically obtained from commercial sources or synthesized using disclosed methods.
[0102] Reaction process
[0103]
[0104] Step 1: Compound Ia undergoes nucleophilic substitution reaction with BrCH2CH2NHPG under alkaline conditions to obtain compound Ib.
[0105] Step 2, reacting compound Ib under appropriate conditions to remove the protecting group PG to obtain compound Ic, wherein PG is an amino protecting group. The types of amino protecting groups and the methods for removing amino protecting groups are well known to those skilled in the art, such as those described in the authoritative discussion, PGM Wuts and TW Greene, Greene's Protective Groups in Organic Synthesis, 4th edition, (Wiley, 2006).
[0106] Step 3, compound Ic is subjected to a condensation reaction with compound Id in the presence of a condensing agent to obtain compound I;
[0107] wherein X1, X2, R1, m and n are as defined herein.
[0108] In a preferred embodiment, in step 1, compound Ia and an alkaline reagent (such as anhydrous potassium carbonate, anhydrous sodium carbonate, sodium hydroxide, potassium hydroxide, triethylamine, diisopropylethylamine, pyridine, etc.) are dissolved in N,N-dimethylformamide, and heated at 60° C. for 0.5 h; (2-bromoethyl) tert-butyl carbamate is added to the reaction solution, and the reaction is continued for 2 h to obtain compound Ib;
[0109] In a preferred embodiment, in step 2, compound Ib is dissolved in ethanol and concentrated hydrochloric acid (V 乙醇 :V 浓盐酸 =2:1) in a mixed solution, reacting at 25°C for 1h to obtain compound Ic;
[0110] In a preferred embodiment, in step 3, compound Ic, compound Id, EDCI and HOBT are dissolved in dichloromethane, triethylamine is added, and the mixture is reacted at 25° C. for 3 h to obtain compound I.
[0111] The present invention is further described below by way of specific embodiments, but this is not intended to limit the present invention. Those skilled in the art may make various modifications or adjustments based on the teachings of the present invention without departing from the spirit and scope of the present invention.
[0112] Example 1 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-phenyl)acrylamide (I-1)
[0113] Step 1: Synthesis of N-tert-butyloxycarbonyl-2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethylamine (Compound 2)
[0114]
[0115] In a dry 50mL single-necked round-bottom flask, add 6-methoxy-2-benzoxazolinone (Compound 1, 0.13g, 0.79mmol), dissolve it with N,N-dimethylformamide (5mL), then add potassium carbonate (0.326g, 2.37mmol), heat to 60℃ and stir to react for 0.5h; then add tert-butyl (2-bromoethyl)carbamate (0.195g, 0.87mmol), and continue to react for 2h. TLC (V 石油醚 :V 乙酸乙酯 =2:1) showed that the reaction was basically complete. 5% dilute hydrochloric acid was added to the reaction solution to precipitate a large amount of white solid, which was filtered, and the filter cake was washed 3 times with a small amount of water and dried to obtain 0.24g of white solid, with a yield of 77.85%. mp144.3-146.2℃. 1H NMR(400MHz,DMSO-d6)δ7.08(d,J=8.6Hz,1H,ArH),7.03(s,1H,ArH),6.94(s,1H,BocNH),6.78(d,J=8.6H z,1H,ArH),3.82–3.76(m,2H,N-CH2),3.74(s,3H,OCH3),3.27–3.18(m,2H,NHCH2),1.26(s,9H,C(CH3)3). 13 CNMR(100MHz,DMSO-d6)δ:155.66,155.38,153.99,142.71,125.12,109.02,108.96,97.10,77.72,55.89,41.84,37.83,28.01.ESI-MSfor C 15 H 20 N2O5:m / z309.1451[M+H] + .
[0116] Step 2: Synthesis of 2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethylamine hydrochloride (3)
[0117]
[0118] In a dry 50 mL single-necked round-bottom flask, compound 2 (0.24 g, 0.78 mmol) was added and concentrated hydrochloric acid / ethanol V 浓盐酸 :V 乙醇 =1:1) mixed solution (4 mL) was dissolved and reacted at 25°C for 1 h. TLC (V 二氯甲烷 :V 甲醇 =2:1) showed that the reaction was basically complete. The reaction solution was filtered, the filter cake was rinsed with ice ethanol three times, and dried to obtain 0.18g of white solid, with a yield of 94.3%. mp258.6-260.6℃. 1 H NMR(400MHz,D2O)δ7.10–7.04(m,1H,ArH),6.93(s,1H,ArH),6.85-6.79(m,1H ,ArH),4.14–4.07(m,2H,NCH2),3.75(s,3H,OCH3),3.41–3.34(m,2H,NHCH2). 13 CNMR(100MHz,D2O)δ156.53,155.86,143.07,123.79,110.16,109.32,97.80,56.15,39.57,37.58.ESI-MS C 10 H 13ClN2O5: m / z 209.0921 [M–Cl] + .
[0119] Step 3: Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-phenyl)acrylamide (I-1)
[0120]
[0121] In a dry 50 mL single-necked round-bottom flask, compound 3 (0.10 g, 0.41 mmol), cinnamic acid (0.06 g, 0.41 mmol), HOBT (0.83 g, 0.62 mmol) and EDCI (0.118 g, 0.62 mmol) were added, dissolved in dichloromethane (5 mL), triethylamine (0.17 mL) was added, and the reaction was stirred at 25 ° C for 3 h. TLC (V 二氯甲烷 :V 甲醇 =15:1) showed that the reaction was basically complete. Dichloromethane (15mL) was added to the reaction solution for dilution, and it was washed with saturated sodium chloride solution (10mL×3). The organic phase was dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure. 0.12g of white solid was obtained by column chromatography separation, with a yield of 86.5%. mp151.0-152.7℃. 1 HNMR(400MHz,DMSO-d6)δ:8.30(t,J=6.0Hz,1H,CO-NH),7.55–7.51(m,2H,ArH),7.37(m,4H,ArCH=,ArH),7.15(d,J=8.6Hz,1H,ArH),7.05(d,J=2.4 Hz,1H,ArH),6.78(dd,J=8.6,2.4Hz,1H,ArH),6.48(d,J=15.8Hz,1H,ArCH=CH),3.90(t,J=5.8Hz,2H,NCH2),3.73(s,3H,OCH3),3.51(m,2H,NHCH2). 13 C NMR(100MHz,DMSO-d6)δ:165.50,155.45,154.10,142.71,138.89,134.73,129.49,1 28.90,127.53,124.76,121.70,109.10,109.08,97.25,55.84,41.55,36.63.ESI-MS C 19 H 18 N2O4:m / z 339.1325[M+H] + .
[0122] Example 2 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-fluorophenyl)acrylamide (I-2)
[0123] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 4-fluorocinnamic acid to obtain 0.15 g of white solid with a yield of 84.2%. mp155.5-156.9℃. 1 H NMR(400MHz,DMSO-d6)δ8.30(t,J=6.0Hz,1H,CO-NH),7.63–7.57(m,2H,ArH),7.38( d,J=15.8Hz,1H,ArCH=),7.24(t,J=8.8Hz,2H,ArH),7.15(d,J=8.6Hz,1H,ArH),7.0 5(d,J=2.4Hz,1H,ArH),6.78(dd,J=8.6,2.4Hz,1H,ArH),6.44(d,J=15.8Hz,1H,ArC H=CH),3.91(t,J=5.8Hz,2H,NCH2),3.73(s,3H,OCH3),3.57–3.48(m,2H,NHCH2).13C NMR(100MHz,DMSO-d6)δ165.43,162.69(J C-F =247.2Hz),155.44,154.10,142.71,137.70,131.37(J C-F =3.2Hz),129.71(J C-F =8.5Hz),124.75,121.60,115.86(J C-F =21.7Hz),109.10,109.08,97.24,55.84,41.55,36.63.ESI-MS C 19 H 17 FN2O4:m / z357.1240[M+H] + .
[0124] Example 3 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-chlorophenyl)acrylamide (I-3)
[0125] Referring to the synthesis method of Example 1, 4-chlorocinnamic acid was used to replace cinnamic acid to obtain 0.2 g of white solid with a yield of 87.9%. mp180.3-181.5℃.1H NMR(400MHz,DMSO-d6)δ8.33(t,J=6.0Hz,1H,CONH),7.57(d,J=8.6Hz,2H,ArH),7 .46(d,J=8.6Hz,2H,ArH),7.36(d,J=15.8Hz,1H,ArCH=),7.15(d,J=8.6Hz,1H,ArH ),7.05(d,J=2.4Hz,1H,ArH),6.78(dd,J=8.6,2.4Hz,1H,ArH),6.50(d,J=15.8Hz, 1H, ArCH=CH), 3.91 (t, J=5.8Hz, 2H, NCH2), 3.73 (s, 3H, OCH3), 3.52 (m, 2H, NHCH2). 13 C NMR(100MHz,DMSO-d6)δ:165.29,155.44,154.09,142.70,137.53,133.90,133.70,1 29.23,128.92,124.73,122.50,109.09,109.07,97.23,55.83,41.52,36.64.ESI-MS C 19 H 17 ClN2O4:m / z 373.0943[M+H] + .
[0126] Example 4 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-methylphenyl)acrylamide (I-4)
[0127] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 4-methylcinnamic acid to obtain 0.145 g of white solid with a yield of 82.3%. mp169.7-170.8℃. 1H NMR(400MHz, DMSO-d6)δ8.27(t,J=6.0Hz,1H,CO-NH),7.42(d,J=8.0Hz,2H,ArH),7.34(d, J=15.8Hz,1H,ArCH=),7.21(d,J=8.0Hz,2H,ArH),7.15(d,J=8.6Hz,1H,ArH),7.05(d,J=2 .4Hz,1H,ArH),6.77(dd,J=8.6,2.4Hz,1H,ArH),6.43(d,J=15.8Hz,1H,ArCH=CH),3.90(t ,J=5.8Hz,2H,NCH2),3.73(s,3H,OCH3),3.55–3.48(m,2H,NHCH2),2.31(s,3H,,Ar-CH3). 13 C NMR (100MHz, DMSO-d6) δ165.64,155.45,154.10,142.71,139.25,138.84,131.99,129. 50,127.51,124.76,120.66,109.11,109.09,97.24,55.84,41.57,36.60,20.92.ESI-MS C 20 H 20 N2O4:m / z 353.1493[M+H] + .
[0128] Example 5 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-trifluoromethylphenyl)acrylamide (I-5)
[0129] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 4-trifluoromethylcinnamic acid to obtain 0.17 g of white solid with a yield of 83.67%. mp190.6-191.3℃. 1 H NMR (400MHz, DMSO-d6) δ8.42(t,J=5.8Hz,1H,CO-NH),7.77-7.74(m,4H,ArH),7.45(d,J=15.8Hz,1H,ArCH=),7.16(d,J=8.6Hz,1H,ArH),7.06(d,J=2.4H z,1H,ArH),6.78(dd,J=8.6,2.4Hz,1H,ArH),6.63(d,J=15.8Hz,1H,ArCH=CH),3.92(t,J=5.8Hz,2H,NCH2),3.73(s,3H,OCH3),3.59–3.50(m,2H,NHCH2). 13C NMR(100MHz,DMSO-d6)δ165.05,155.46,154.11,142.72,138.83,137.23,129.24(J C-F =31.9Hz),128.17,125.75(J C-F =4.0Hz),124.73,124.49,124.08(J C-F =270.1Hz),109.11,109.08,97.25,55.83,41.51,36.68.ESI-MS C 20 H 17 F3N2O4:m / z 407.1204[M+H] + .
[0130] Example 6 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-hydroxyphenyl)acrylamide (I-6)
[0131] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 4-hydroxycinnamic acid to obtain 0.085 g of white solid with a yield of 48.0%. mp230.0-231.8℃. 1 H NMR (400MHz, DMSO-d6) δ9.84(s,1H,OH),8.18(t,J=6.0Hz,1H,CO-NH),7.37(d,J=8.6Hz,2H,ArH),7.28(d,J=15.8Hz,1H ArCH=),7.14(d,J=8.6Hz,1H,ArH),7.05(d,J=2.4Hz,1H,ArH),6.81–6.75(m,3H,ArH),6.27(d,J =15.8Hz,1H,ArCH=CH),3.89(t,J=5.8Hz,2H,NCH2),3.73(s,3H,OCH3),3.53–3.46(m,2H,NHCH2). 13 CNMR(100MHz,DMSO-d6)δ165.95,158.90,155.44,154.10,142.71,139.03,129. 28,125.74,124.79,118.12,115.73,109.10,97.25,55.85,41.62,36.59.ESI-MS C 19 H 18 N2O5:m / z355.1278[M+H] + .
[0132] Example 7 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide (I-7)
[0133] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 4-hydroxy-3-methoxycinnamic acid, and column chromatography was used for purification to obtain 0.15 g of a white solid with a yield of 65.04%. mp 234.0-235.3℃. 1 H NMR (400MHz, DMSO-d6) δ9.43 (s, 1H, OH), 8.16 (t, J = 6.0Hz, 1H, CO-NH), 7.28 (d, J = 15.8Hz, 1H ,ArCH=),7.14(d,J=8.6Hz,1H,ArH),7.10(d,J=2.0Hz,1H,ArH),7.05(d,J=2.4Hz,1H,ArH), 6.97(dd,J=8.2,2.0Hz,1H,ArH),6.83–6.75(m,2H,ArH),6.31(d,J=15.8Hz,1H,ArCH=CH),3 .89(t,J=5.8Hz,2H,NCH2),3.80(s,3H,OCH3),3.73(s,3H,OCH3),3.55–3.47(m,2H,NHCH2). 13 C NMR(100MHz,DMSO-d6)δ165.96,155.45,154.11,148.35,147.81,142.72,139.33,126.24,1 24.78,121.63,118.43,115.64,110.80,109.11,97.24,55.85,55.52,41.64,36.58.ESI-MSC 20 H 20 N2O6:m / z 385.1383[M+H] + .
[0134] Example 8 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-methoxyphenyl)acrylamide (I-8)
[0135] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 4-methoxycinnamic acid to obtain 0.15 g of white solid with a yield of 81.44%. mp165.4-166.5℃. 1H NMR(400MHz, DMSO-d6)δ8.22(t,J=6.0Hz,1H,CO-NH),7.48(d,J=8.8Hz,2H,ArH),7.33(d ,J=15.8Hz,1H,ArCH=),7.15(d,J=8.6Hz,1H,ArH),7.05(d,J=2.4Hz,1H,ArH),6.96(d,J =8.8Hz,2H,ArH),6.78(dd,J=8.6,2.4Hz,1H,ArH),6.34(d,J=15.8Hz,1H,ArCH=CH),3.8 9(t,J=5.8Hz,2H,NCH2),3.78(s,3H,OCH3),3.73(s,3H,OCH3),3.54–3.48(m,2H,NHCH2). 13 C NMR (100MHz, DMSO-d6) δ: 165.79, 160.35, 155.44, 154.09, 142.71, 138.61, 129.13, 127. 30,124.77,119.20,114.35,109.11,109.09,97.24,55.84,55.24,41.60,36.59.ESI-MS C 20 H 20 N2O5:m / z 369.1433[M+H] + .
[0136] Example 9 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4-dimethoxyphenyl)acrylamide (I-9)
[0137] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 3,4-dimethoxycinnamic acid to obtain 0.15 g of white solid with a yield of 75.3%. mp146.1-147.9℃. 1H NMR(400MHz, DMSO-d6)δ8.19(t,J=6.0Hz,1H,CO-NH),7.32(d,J=15.8Hz,1H,ArCH=),7.15(d,J=8.6Hz ,1H,ArH),7.12(d,J=2.0Hz,1H,ArH),7.09(dd,J=8.4,2.0Hz,1H,ArH),7.05(d,J=2.4Hz,1H,ArH),6. 97(d,J=8.4Hz,1H,ArH),6.78(dd,J=8.6,2.4Hz,1H,ArH),6.38(d,J=15.8Hz,1H,ArCH=CH),3.90(t,J =5.8Hz,2H,NCH2),3.79(s,3H,OCH3),3.78(s,3H,OCH3),3.73(s,3H,OCH3),3.55–3.48(m,2H,NHCH2). 13 CNMR(100MHz,DMSO-d6)δ165.81,155.44,154.10,150.15,148.88,142.72,138.98,127.53,124 .76,121.44,119.41,111.70,109.98,109.11,97.23,55.85,55.52,55.40,41.62,36.59.ESI-MS C 21 H 22 N2O6:m / z 399.1536[M+H] + .
[0138] Example 10 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (I-10)
[0139] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 3,4,5-trimethoxycinnamic acid to obtain 0.18 g of white solid with a yield of 84.03%. mp148.6-149.3℃. 1H NMR (400MHz, DMSO-d6) δ8.23 (t, J=6.0Hz, 1H, CO-NH), 7.31 (d, J=15.8Hz, 1H, ArCH=) ,7.15(d,J=8.6Hz,1H,ArH),7.06(d,J=2.4Hz,1H,ArH),6.86(s,2H,ArH),6.78(dd,J =8.6,2.4Hz,1H,ArH),6.44(d,J=15.8Hz,1H,ArCH=CH),3.90(t,J=5.8Hz,2H,NCH2) ,3.81(s,6H,OCH3),3.73(s,3H,OCH3),3.68(s,3H,OCH3),3.56–3.48(m,2H,NHCH2). 13 C NMR(100MHz,DMSO-d6)δ165.60,155.45,154.11,153.06,142.73,139.08,138.70,1 30.36,124.77,121.06,109.12,104.98,97.24,60.08,55.86,41.60,36.60.ESI-MS C 22 H 24 N2O7:m / z 429.1647[M+H] + .
[0140] Example 11 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-methoxyphenyl)acrylamide (I-11)
[0141] Referring to the synthesis method of Example 1, 2-methoxycinnamic acid was used to replace cinnamic acid to obtain 0.1 g of white solid with a yield of 82.27%. mp185.1-186.6℃. 1H NMR (400MHz, DMSO-d6) δ8.29(t,J=6.0Hz,1H,CO-NH),7.62(d,J=15.8Hz,1H,ArCH=),7.48(d ,J=7.6Hz,1H,ArH),7.40–7.32(m,1H,ArH)7.15(d,J=8.6Hz,1H,ArH),7.10–7.01(m,2H,ArH) ,7.00–6.93(m,1H,ArH),6.78(dd,J=8.6,2.4Hz,1H,ArH),6.51(d,J=15.8Hz,1H,ArCH=CH), 3.90(t,J=5.8Hz,2H,NCH2),3.85(s,3H,OCH3),3.73(s,3H,OCH3),3.55–3.47(m,2H,NHCH2). 13 C NMR(100MHz,DMSO-d6)δ165.86,157.52,155.44,154.08,142.70,133.92,130.88,127.85,1 24.76,123.10,122.02,120.66,111.67,109.10,97.24,55.83,55.53,41.58,36.61.ESI-MS C 20 H 20 N2O5:m / z 369.1436[M+H] + .
[0142] Example 12 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3-methoxyphenyl)acrylamide (I-12)
[0143] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 3-methoxycinnamic acid to obtain 0.13 g of white solid with a yield of 86.09%. mp127.6-128.9℃. 1H NMR (400MHz, DMSO-d6) δ8.30 (t, J=6.0Hz, 1H, CO-NH), 7.37–7.29 (m, 2H, ArCH=, ArH), 7.1 5(d,J=8.6Hz,1H,ArH),7.13–7.07(m,2H,ArH),7.05(d,J=2.4Hz,1H,ArH),6.95(dd,J=8. 2,1.6Hz,1H,ArH),6.78(dd,J=8.6,2.4Hz,1H,ArH),6.50(d,J=15.8Hz,1H,ArCH=CH),3.9 0(t,J=5.8Hz,2H,NCH2),3.78(s,3H,OCH3),3.73(s,3H,OCH3),3.57–3.48(m,2H,NHCH2). 13 C NMR (100MHz, DMSO-d6) δ165.47,159.57,155.44,154.10,142.71,138.82,136.18,129.94,124. 75,122.04,119.90,115.32,112.60,109.11,109.09,97.24,55.84,55.09,41.56,36.62.ESI-MS C 20 H 20 N2O5:m / z 369.1434[M+H] + .
[0144] Example 13 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-chlorophenyl)acrylamide (I-13)
[0145] Referring to the synthesis method of Example 1, 2-chlorocinnamic acid was used to replace cinnamic acid to obtain 0.15 g of white solid with a yield of 80.48%. mp166.4-167.8℃. 1H NMR(400MHz,DMSO-d6)δ8.42(t,J=6.0Hz,1H,CO-NH),7.71–7.63(m,2H,ArCH=,Ar H),7.56–7.49(m,1H,ArH),7.45–7.35(m,2H,ArH),7.16(d,J=8.6Hz,1H,ArH),7.0 6(d,J=2.4Hz,1H,ArH),6.78(dd,J=8.6,2.6Hz,1H,ArH),6.53(d,J=15.8Hz,1H,Ar CH=CH),3.91(t,J=5.8Hz,2H,NCH2),3.73(s,3H,OCH3),3.58–3.48(m,2H,NHCH2). 13 C NMR(100MHz,DMSO-d6)δ165.03,155.45,154.10,142.71,134.14,133.29,132.53,130.95,1 29.96,127.74,127.55,124.75,124.73,109.12,109.10,97.24,55.83,41.48,36.69.ESI-MS C 19 H 17 ClN2O4:m / z 373.0941[M+H] + .
[0146] Example 14 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3-chlorophenyl)acrylamide (I-14)
[0147] Referring to the synthesis method of Example 1, 3-chlorocinnamic acid was used to replace cinnamic acid to obtain 0.14 g of white solid with a yield of 75.11%. mp141.1-142.8℃. 1H NMR(400MHz,DMSO-d6)δ8.31(t,J=6.0Hz,1H,CO-NH),7.62–7.59(m,1H,ArH),7.53–7.4 8(m,1H,ArH),7.46–7.41(m,2H,ArH),7.35(d,J=15.8Hz,1H,ArCH=),7.15(d,J=8.6Hz,1 H, ArH), 7.05 (d, J = 2.4Hz, 1H, ArH), 6.78 (dd, J = 8.6, 2.4Hz, 1H, ArH), 6.55 (d, J = 15.8Hz, 1H,ArCH=CH),3.91(t,J=5.8Hz,2H,NCH2),3.73(s,3H,OCH3),3.58–3.50(m,2H,NHCH2). 13 C NMR(100MHz,DMSO-d6)δ165.18,155.44,154.10,142.71,137.35,137.05,133.65,130.70,1 29.10,127.20,126.02,124.74,123.38,109.10,109.06,97.24,55.83,41.51,36.65.ESI-MS C 19 H 17 ClN2O4:m / z 373.0944[M+H] + .
[0148] Example 15 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-cyanophenyl)acrylamide (I-15)
[0149] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 4-cyanocinnamic acid to obtain 0.16 g of white solid with a yield of 75.11%. mp141.1-142.8℃. 1H NMR (400MHz, DMSO-d6) δ8.40 (t, J=6.0Hz, 1H, CO-NH), 7.86 (d, J=8.4Hz, 2H, ArH), 7. 73(d,J=8.4Hz,2H,ArH),7.41(d,J=15.8Hz,1H,ArCH=),7.15(d,J=8.6Hz,1H,ArH), 7.05(d,J=2.4Hz,1H,ArH),6.77(dd,J=8.6,2.4Hz,1H,ArH),6.62(d,J=15.8Hz,1H, ArCH=CH),3.91(t,J=5.8Hz,2H,NCH2),3.72(s,3H,OCH3),3.56–3.47(m,2H,NHCH2). 13 CNMR(100MHz,DMSO-d6)δ164.95,155.44,154.10,142.71,139.38,137.11,132.77,128. 24,125.13,124.72,118.64,111.44,109.10,109.08,97.24,55.83,41.49,36.70.ESI-MS C 20 H 17 N3O4:m / z 364.1283[M+H] + .
[0150] Example 16 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-pyridyl)acrylamide (I-16)
[0151] Referring to the synthesis method of Example 1, pyridine-2-propenoic acid was used to replace cinnamic acid to obtain 0.14 g of white solid with a yield of 72.38%. mp162.8-164.6℃. 1H NMR(400MHz,DMSO-d6)δ8.63–8.56(m,1H,Py-H),8.49(t,J=6.0Hz,1H,CO-NH),7.87–7.78 (m,1H,Py-H),7.60–7.53(m,1H,Py-H),7.44–7.33(m,2H,PyCH=,,Py-H),7.15(d,J=8.6Hz ,1H,ArH),7.06(d,J=2.4Hz,1H,ArH),6.94(d,J=15.4Hz,1H,PyCH=CH),6.78(dd,J=8.6,2 .5Hz,1H,ArH),3.92(t,J=5.8Hz,2H,NCH2),3.73(s,3H,OCH3),3.58–3.49(m,2H,NHCH2). 13 C NMR(100MHz,DMSO-d6)δ165.22,155.43,154.10,152.86,149.77,142.71,138.18,137.1 6,125.29,124.75,124.24,124.02,109.09,109.06,97.23,55.83,41.52,36.63.ESI-MS C 18 H 17 N3O4:m / z 340.1278[M+H] + .
[0152] Example 17 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(1,3-benzodiazole-5-yl)acrylamide (I-17)
[0153] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 3,4-(methylenedioxy)cinnamic acid to obtain 0.17 g of white solid with a yield of 88.92%. mp166.9-168.7℃. 1H NMR (400MHz, DMSO-d6) δ8.19 (t, J=6.0Hz, 1H, CO-NH), 7.29 (d, J=15.8Hz, 1H, ArC H=),7.18–7.11(m,2H,ArH),7.07–7.01(m,2H,ArH),6.93(d,J=8.0Hz,1H,ArH), 6.78(dd,J=8.6,2.4Hz,1H,ArH),6.33(d,J=15.8Hz,1H,ArCH=CH),6.06(s,2H,O CH2O),3.89(t,J=5.8Hz,2H,NCH2),3.73(s,3H,OCH3),3.55–3.45(m,2H,NHCH2). 13 C NMR(100MHz,DMSO-d6)δ165.72,155.44,154.10,148.50,147.93,142.71,138.75,129.13,124.7 7,123.33,119.76,109.12,109.10,108.55,106.23,101.44,97.24,55.85,41.58,36.62.ESI-MS C 20 H 18 N2O6:m / z 383.1228[M+H] + .
[0154] Example 18 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-thienyl)acrylamide (I-18)
[0155] Referring to the synthesis method of Example 1, cinnamic acid was replaced by thiophene-2-propenoic acid to obtain 0.16 g of white solid with a yield of 81.52%. mp166.6-168.0℃. 1H NMR (400 MHz, DMSO-d6) δ8.29 (t, J = 6.0 Hz, 1H, CO-NH), 7.60 (d, J = 5.2 Hz, 1H, thiophene-H), 7.53 (d, J = 15.5 Hz, 1H, thiophene-CH =), 7.36 (d, J = 3.6 Hz, 1H, thiophene-H), 7.15 (d, J = 8.6 Hz, 1H, ArH), 7.10 (dd, J = 5.1, 3.6 Hz, 1H, thiophene-H), 7.05 (d, J = 2.4 Hz, 1H, ArH), 6.78 (dd, J = 8.6, 2.5 Hz, 1H, ArH), 6.24 (d, J = 15.4 Hz, 1H, thiophene-CH = CH), 3.89 (t, J = 5.8 Hz, 2H, NCH2), 3.74 (s, 3H, OCH3), 3.54–3.46 (m, 2H, NHCH2). 13 C NMR(100MHz,DMSO-d6)δ165.18,155.45,154.09,142.70,139.66,131.91,130.65,1 28.31,127.94,124.71,120.36,109.09,109.07,97.24,55.84,41.58,36.56.ESI-MS C 17 H 16 N2O4S:m / z345.0907[M+H] + .
[0156] Example 19 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-furyl)acrylamide (I-19)
[0157] Referring to the synthesis method of Example 1, furan-2-acrylic acid was used to replace cinnamic acid to obtain 0.138 g of a white solid with a yield of 55.0%. mp162.4-163.8°C. 1H NMR (400MHz, DMSO-d6) δ8.33 (t, J=6.0Hz, 1H, CO-NH), 7.77–7.74 (m, 1H, furan-H), 7.19 (d, J=15.6Hz, 1H, furan-CH=), 7.13 (d, J=8.6Hz, 1H, ArH), 7.05 (d, J=2.4Hz, 1H, ArH), 6.80 -6.75 (m, 2H, ArH, furan-H), 6.58 (dd, J = 3.4, 1.8 Hz, 1H, furan-H), 6.27 (d, J = 15.6 Hz, 1H, furan-CH = CH), 3.89 (t, J = 5.8 Hz, 2H, NCH2), 3.74 (s, 3H, OCH3), 3.55-3.45 (m, 2H, NHCH2).13C NMR(100MHz,DMSO-d6)δ165.27,155.43,154.08,150.81,144.74,142.69,126.20,1 24.74,118.93,113.83,112.35,109.09,109.05,97.23,55.84,41.55,36.60.ESI-MS C 17 H 16 N2O5:m / z 329.1136[M+H] + .
[0158] Example 20 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3-furyl)acrylamide (I-20)
[0159] Referring to the synthesis method of Example 1, furan-3-acrylic acid was used to replace cinnamic acid to obtain 0.14 g of a light yellow solid with a yield of 71.06%. mp157.5-159.0°C. 1H NMR (400MHz, DMSO-d6) δ8.21 (t, J=6.0Hz, 1H, CO-NH), 7.99 (s, 1H, furan-H), 7.73-7.69 (m, 1H, furan-H), 7.28 (d, J=15.6Hz, 1H, furan-CH=), 7.13 (d, J=8.6Hz, 1H, ArH), 7.05 (d, J=2.4Hz, 1H ,ArH), 6.78(dd,J=8.6,2.4Hz,1H,ArH), 6.73–6.69(m,1H,furan-H), 6.19(d,J=15.6Hz,1H,furan-CH=CH), 3.89(t,J=5.8Hz,2H,NCH2), 3.74(s,3H,OCH3), 3.52–3.45(m,2H,NHCH2).13C NMR(100MHz,DMSO-d6)δ165.61,155.44,154.09,144.78,144.50,142.70,129.29,1 24.76,122.48,121.22,109.09,109.07,107.57,97.23,55.85,41.57,36.56.ESI-MS C 17 H 16 N2O5:m / z 329.1126[M+H] + .
[0160] Example 21 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(5-methyl-2-furyl)acrylamide (I-21)
[0161] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 5-methyl-2-furan acrylic acid to obtain 0.128 g of white solid with a yield of 74.78%. mp 176.6-178.5℃. 1H NMR (400 MHz, DMSO-d6) 8.24 (t, J = 6.0 Hz, 1H, CO-NH), 7.15–7.08 (m, 2H, furan-CH=, ArH), 7.05 (d, J = 2.4 Hz, 1H, ArH), 6.78 (dd, J = 8.6, 2.4 Hz, 1H, ArH), 6.64 (d, J = 3.2 Hz, 1H, furan-H), 6.22–6.14 (m, 2H, furan-CH=CH, furan-H), 3.88 (t, J = 5.8 Hz, 2H, NCH2), 3.74 (s, 3H, OCH3), 3.53–3.46 (m, 2H, NHCH2), 2.30 (s, 3H, CH3). 13 C NMR (100MHz, DMSO-d6) δ165.45,155.42,154.07,154.02,149.46,142.69,126.17,124. 75,117.41,115.30,109.10,109.03,108.76,97.20,55.84,41.58,36.54,13.44.ESI-MS C 18 H 18 N2O5:m / z 343.1294[M+H] + .
[0162] Example 22 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(5-bromo-2-furyl)acrylamide (I-22)
[0163] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 5-bromo-2-furan acrylic acid to obtain 0.18 g of white solid with a yield of 88.4%. mp160.3-162.2℃.1H NMR (400 MHz, DMSO-d6) δ8.32 (t, J = 6.0 Hz, 1H, CO-NH), 7.17–7.08 (m, 2H, furan-CH=, ArH), 7.05 (d, J = 2.4 Hz, 1H, ArH), 6.81 (d, J = 3.4 Hz, 1H, furan-H), 6.78 (dd, J = 8.6, 2.4 Hz, 1H, ArH), 6.70 (d, J = 3.4 Hz, 1H, furan-H), 6.27 (d, J = 15.6 Hz, 1H, furan-CH=CH), 3.89 (t, J = 5.8 Hz, 2H, NCH2), 3.74 (s, 3H, OCH3), 3.54–3.48 (m, 2H, NHCH2).13C NMR(100MHz,DMSO-d6)δ164.96,155.43,154.07,153.03,142.69,125.11,124.70,1 23.80,119.57,116.19,114.42,109.08,109.04,97.22,55.84,41.53,36.58.ESI-MS C 17 H 15 BrN2O5:m / z 407.0242[M+H] + .
[0164] Example 23 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(1-benzofuran-2-yl)acrylamide (I-23)
[0165] Referring to the synthesis method of Example 1, (2E)-3-(1-benzofuran-2-yl)prop-2-enoic acid was used to replace cinnamic acid to obtain 0.16 g of a white solid with a yield of 84.6%. mp187.3-188.4°C. 1H NMR (400MHz, DMSO-d6) δ8.46 (t, J=6.0Hz, 1H, CO-NH), 7.67 (d, J=7.4Hz, 1H, ArH), 7.59-7.55 (m, 1H, ArH), 7.41-7.34 (m, 2H, furan-CH=, ArH), 7.30-7.24 (m, 1H, ArH), 7.22 (s, 1H, furan-H), 7.16 (d, J=7.4Hz, 1H, ArH). =8.6Hz,1H,ArH),7.06(d,J=2.4Hz,1H,ArH),6.78(dd,J=8.6,2.4Hz,1H,ArH),6.56(d,J=15.6H z,1H,furan-CH=CH),3.92(t,J=5.8Hz,2H,NCH2),3.73(s,3H,OCH3),3.59–3.51(m,2H,NHCH2).13C NMR(100MHz,DMSO-d6)δ164.86,155.43,154.52,154.09,152.70,142.70,128.19,126.40,126.05,1 24.72,123.35,122.27,121.76,111.06,110.07,109.08,109.04,97.22,55.82,41.53,36.65.ESI-MS C 21 H 18 N2O5:m / z 379.1288[M+H] + .
[0166] Example 24 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(5-nitro-2-furyl)acrylamide (I-24)
[0167] Referring to the synthesis method of Example 1, 5-nitro-2-furan acrylic acid was used to replace cinnamic acid to obtain 0.115 g of a yellow solid with a yield of 61.7%. mp241.8-243.4°C. 1H NMR (400MHz, DMSO-d6) δ8.57 (t, J=6.0Hz, 1H, CO-NH), 7.73 (d, J=3.8Hz, 1H, furan-H), 7.28 (d, J=15.8Hz, 1H, furan-CH=), 7.15 (d, J=8.6Hz, ArH, 1H), 7.12 (d, J=3.9Hz, 1H, furan-H), 7.70 (d, J=1.3Hz, 1H, furan-CH=), 7.62 (d, J=1.6Hz, 1H, furan-CH=), 7.50 (d, J=1.6Hz, 1H, furan-CH=), 7.40 (d, J=1.6Hz, 1H, furan-CH=), 7.30 (d, J=1.6Hz, 1H, furan-CH=), 7.20 (d, J=1.6Hz, 1H, furan-CH=), 7. .05 (d, J = 2.4 Hz, 1H, ArH), 6.78 (dd, J = 8.6, 2.4 Hz, 1H, ArH), 6.63 (d, J = 15.8 Hz, 1H, furan-CH = CH), 3.91 (t, J = 5.8 Hz, 2H, NCH2), 3.74 (s, 3H, OCH3), 3.58–3.49 (m, 2H, NHCH2).13C NMR(100MHz,DMSO-d6)δ164.10,155.45,154.10,153.13,151.54,142.70,125.31,1 24.64,124.60,116.09,114.64,109.11,109.06,97.22,55.84,41.46,36.67.ESI-MS C 17 H 15 N3O7:m / z 374.0985[M+H] + .
[0168] Example 25 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-2-benzofuranamide (I-25)
[0169] Referring to the synthesis method of Example 1, cinnamic acid was replaced by benzofuran-2-carboxylic acid to obtain 0.09 g of white solid with a yield of 51.1%. mp154.4-160.1℃.1H NMR (400MHz, DMSO-d6) δ8.91 (t, J=6.0Hz, 1H, CO-NH), 7.76 (d, J=7.6Hz, 1H, ArH), 7.65–7.58(m,1H,ArH),7.50-7.42(m,2H,ArH,furan-H),7.38–7.29(m,1H,ArH),7.1 6(d,J=8.6Hz,1H,ArH),7.04(d,J=2.4Hz,1H,ArH),6.72(dd,J=8.6,2.4Hz,1H,Ar H),3.97(t,J=5.8Hz,2H,NCH2),3.70(s,3H,OCH3),3.64-3.55(m,2H,NHCH2).13C NMR(100MHz,DMSO-d6)δ158.54,155.39,154.17,154.12,148.89,142.71,127.08,126.8 1,124.81,123.67,122.75,111.70,109.47,108.98,97.23,55.81,41.42,36.83.ESI-MS C 19 H 16 N2O5: m / z 353.1127[M+H] + .
[0170] Example 26 Synthesis of (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-2-furanamide (I-26)
[0171] Referring to the synthesis method of Example 1, cinnamic acid was replaced by 2-furancarboxylic acid to obtain 0.11 g of a white solid with a yield of 72.8%. mp132.8-133.4℃.1H NMR (400MHz, DMSO-d6)δ:8.53(t,J=6.0Hz,1H,CO-NH),7.84–7.74(m,1H,furan-H),7.12(d,J=8.6Hz,1H,ArH),7.04(d,J=2.4Hz,1H,ArH),7.01–6.96(m,1H,furan-H),6.74(dd,J=8.6,2.4Hz,1H,ArH),6.58(dd,J=3.5,1.8Hz,1H,furan-H),3.91(t,J=5.8Hz,2H,NCH2),3.73(s,3H,OCH3),3.57-3.49(m,2H,NHCH2).13C NMR(100MHz,DMSO-d6)δ158.13,155.40,154.08,147.69,144.99,142.69,1 24.81,113.43,111.77,109.02,108.98,97.20,55.85,41.49,36.54.ESI-MS C 15 H 14 N2O5:m / z 303.0952[M+H] + .
[0172] Example 27 Synthesis of (E)-N-(2-(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-furyl)acrylamide (I-27)
[0173] Step 1: Synthesis of N-tert-butyloxycarbonyl-2-(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethylamine (Compound 5)
[0174]
[0175] In a dry 50mL single-necked round-bottom flask, add 2-benzoxazolinone (0.27g, 2.0mmol), dissolve it with N,N-dimethylformamide (5mL), then add potassium carbonate (0.83g, 6.0mmol), heat to 60℃ and stir to react for 0.5h; then add tert-butyl (2-bromoethyl) carbamate (0.54g, 2.4mmol), and continue to react for 2h. TLC (V 石油醚 :V 乙酸乙酯 =2:1) showed that the reaction was basically complete. 5% dilute hydrochloric acid was added to the reaction solution to precipitate a large amount of white solid, which was filtered, and the filter cake was washed 3 times with a small amount of water and dried to obtain 0.37 g of white solid, with a yield of 66.5%.
[0176] Step 2: Synthesis of 2-(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethylamine hydrochloride (Compound 6)
[0177]
[0178] In a dry 50 mL single-necked round-bottom flask, compound 5 (0.36 g, 1.3 mmol) was added and concentrated hydrochloric acid / ethanol (V 浓盐酸 :V 乙醇 =1:1) mixed solution (4 mL) was dissolved and reacted at 25°C for 1 h. TLC (V 二氯甲烷 :V 甲醇 =2:1) indicating that the reaction was basically complete. The reaction solution was filtered, the filter cake was rinsed with ice ethanol three times, and dried to obtain 0.26 g of white solid, with a yield of 93.2%.
[0179] Step 3: Synthesis of (E)-N-(2-(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-furyl)acrylamide (I-27)
[0180]
[0181] In a dry 50 mL single-necked round-bottom flask, compound 6 (0.107 g, 0.5 mmol), furan-2-acrylic acid (0.70 g, 0.5 mmol), HOBT (0.101 g, 0.75 mmol) and EDCI (0.144 g, 0.75 mmol) were added, dissolved in dichloromethane (5 mL), triethylamine (0.21 mL) was added, and the reaction was stirred at 25 ° C for 3 h. TLC (V 二氯甲烷 :V 甲醇 =15:1) showed that the reaction was basically complete. Dichloromethane (15mL) was added to the reaction solution, washed with saturated sodium chloride solution (10mL×3), the organic phase was dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure. Column chromatography purification gave 0.80g of white solid with a yield of 53.7%. mp166.0-167.1℃. 1HNMR (400 MHz, DMSO-d6) δ8.34 (t, J = 6.0 Hz, 1H, CO-NH), 7.75 (d, J = 1.8 Hz, 1H, furan-H), 7.33 (d, J = 7.8 Hz, 1H, ArH), 7.25–7.15 (m, 3H, ArCH=, ArH), 7.13–7.08 (m, 1H, ArH), 6.76 (d, J = 3.4 Hz, 1H, furan-H), 6.57 (dd, J = 3.4, 1.8 Hz, 1H, furan-H), 6.25 (d, J = 15.6 Hz, 1H, ArCH=CH), 3.92 (t, J = 5.8 Hz, 2H, NCH2), 3.55–3.48 (m, 2H, NHCH2). 13 C NMR(100MHz,DMSO-d6)δ165.31,153.86,150.81,144.76,142.03,131.30,126.24 ,123.76,122.06,118.91,113.89,112.38,109.56,108.92,41.59,36.61.ESI-MS C 16 H 14 N2O4:m / z 321.0819[M+Na] + .
[0182] Example 28 Synthesis of (E)-N-(2-(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (I-28)
[0183] Referring to the synthesis method of Example 27, 3,4,5-trimethoxycinnamic acid was used to replace furan-2-acrylic acid to obtain 0.22 g of white solid with a yield of 72.5%. mp 176.6-178.5℃. 1 H NMR(400MHz, DMSO-d6)δ8.24(t,J=6.0Hz,1H,CO-NH),7.35–7.28(m,2H,ArH,ArCH=),7.27–7.23(m,1H,ArH),7.23–7.17(m,1H,ArH),7.14–7.09(m,1H, ArH),6.85(s,2H,ArH),6.43(d,J=15.8Hz,1H,ArCH=CH),3.94(t,J=5.8Hz,2H,NCH2),3.80(s,6H,OCH3),3.68(s,3H,OCH3),3.56–3.49(m,2H,NHCH2). 13CNMR(100MHz,DMSO-d6)δ165.61,153.86,153.05,142.04,139.08,138.70,131.31,130.3 4,123.76,122.05,121.03,109.56,108.96,104.97,60.06,55.86,41.61,36.60.ESI-MSC 21 H 21 BrN2O6:m / z 399.1541[M+H] + .
[0184] Example 29 Synthesis of (E)-N-(2-(6-bromo-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-furyl)acrylamide (I-29)
[0185] Step 1: Synthesis of N-tert-butyloxycarbonyl-2-(6-bromo-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethylamine (Compound 8)
[0186]
[0187] In a dry 50mL single-necked round-bottom flask, add compound 6-bromo-benzoxazolinone (0.856g, 4.0mmol), dissolve it with N,N-dimethylformamide (5mL), then add potassium carbonate (1.66g, 12.0mmol), heat to 60℃ and stir to react for 0.5h; then add tert-butyl (2-bromoethyl) carbamate (0.986g, 4.4mmol), and continue to react for 2h. TLC (V 石油醚 :V 乙酸乙酯 =2:1) showed that the reaction was basically complete. 5% dilute hydrochloric acid was added to the reaction solution to precipitate a large amount of white solid, which was filtered, and the filter cake was washed 3 times with a small amount of water and dried to obtain 1.2 g of white solid, with a yield of 84.0%.
[0188] Step 2: Synthesis of 2-(6-bromo-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethylamine hydrochloride (Compound 9)
[0189]
[0190] In a dry 50 mL single-necked round-bottom flask, compound 8 (1.0 g, 2.8 mmol) was added and concentrated hydrochloric acid / ethanol was used to obtain a 50 mL single-necked round-bottom flask. 浓盐酸 :V 乙醇 =1:1) mixed solution (6 mL) was dissolved and reacted at 25°C for 1 h. TLC (V 二氯甲烷 :V 甲醇=2:1) indicating that the reaction was basically complete. The reaction solution was filtered, the filter cake was rinsed with ice ethanol three times, and dried to obtain 0.79 g of white solid, with a yield of 96.1%.
[0191] Step 3: Synthesis of (E)-N-(2-(6-bromo-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-furyl)acrylamide (I-29)
[0192]
[0193] In a dry 50 mL single-necked round-bottom flask, compound 9 (0.147 g, 0.5 mmol), furan-2-acrylic acid (0.079 g, 0.55 mmol), HOBT (0.101 g, 0.75 mmol) and EDCI (0.144 g, 0.75 mmol) were added, dissolved in dichloromethane (5 mL), triethylamine (0.21 mL) was added, and the reaction was stirred at 25 ° C for 3 h. TLC (V 二氯甲烷 :V 甲醇 =15:1) showed that the reaction was basically complete. Dichloromethane (15mL) was added to the reaction solution, washed with saturated sodium chloride solution (10mL×3), the organic phase was dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure. Column chromatography purification gave 0.95g of white solid, with a yield of 50.3%. mp165.5-166.2℃. 1 H NMR (400 MHz, DMSO-d6) δ8.31 (t, J = 6.0 Hz, 1H, CO-NH), 7.76 (d, J = 2.2 Hz, 1H, ArH), 7.66 (d, J = 1.8 Hz, 1H, furan-H), 7.40 (dd, J = 8.4, 2.0 Hz, 1H, ArH), 7.21 (d, J = 8.4 Hz, 1H, ArH), 7.17 ( d, J = 15.8 Hz, 1H, ArCH =), 6.76 (d, J = 3.4 Hz, 1H, furan-H), 6.58 (dd, J = 3.4, 1.8 Hz, 1H, furan-H), 6.24 (d, J = 15.8 Hz, 1H, ArCH = CH), 3.92 (t, J = 5.7 Hz, 2H, NCH2), 3.53–3.47 (m, 2H, NHCH2). 13 C NMR(100MHz,DMSO-d6)δ165.32,153.49,150.77,144.78,142.67,130.88,126.44 ,126.27,118.80,113.92,113.32,112.85,112.38,110.47,41.85,36.44.ESI-MS C 16 H 13BrN2O4: m / z 377.0118[M+H] + .
[0194] Example 30 Synthesis of (E)-N-(2-(6-bromo-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (I-30)
[0195] Referring to the synthesis method of Example 29, 3,4,5-trimethoxycinnamic acid was used to replace furan-2-acrylic acid to obtain 0.34 g of white solid with a yield of 71.2%. mp 176.6-178.5℃. 1 H NMR (400MHz, DMSO-d6) δ8.21 (t, J=6.0Hz, 1H, CO-NH), 7.66 (d, J=2.0Hz, 1H, ArH ),7.40(dd,J=8.4,1.8Hz,1H,ArH),7.28(d,J=15.8Hz,1H,ArCH=),7.22(d,J=8. 4Hz, 1H, ArH), 6.85 (s, 2H, ArH), 6.41 (d, J = 15.8Hz, 1H, ArCH = CH), 3.92 (t, J = 5. 8Hz,2H,NCH2),3.80(s,6H,OCH3),3.68(s,3H,OCH3),3.54–3.49(m,2H,NHCH2). 13 CNMR(100MHz,DMSO-d6)δ165.64,153.50,153.05,142.68,139.12,138.70,130.90,130. 31,126.43,120.95,113.31,112.85,110.51,104.97,60.06,55.86,41.88,36.45.ESI-MS C 21 H 21 BrN2O6:m / z 477.0649[M+H] + .
[0196] Biological Activity
[0197] 1. Effects of compounds on LPS-induced NO secretion in RAW 264.7 cells
[0198] (1) Experimental methods
[0199] RAW 264.7 cells (purchased from ATCC, Rockville, MD, USA) were seeded on a 96-well plate, pretreated with DMSO solvent or compound (final concentration of 20 μM) for 2 h, and then stimulated with LPS (purchased from Sigma, a, St. Louis, MO, USA, final concentration of 0.5 μg / mL) for 24 h. The supernatant of the cells was added with Griess reagent (purchased from Beyotime, Shanghai, China) for color development, mixed, incubated at room temperature for 10 min, and the absorbance was measured by A540. The concentration of NO in the sample was calculated based on the standard curve. RAW 264.7 cells were seeded on a 96-well plate, pretreated with DMSO solvent or compound of different concentrations (0-40 μM) for 2 h, and then stimulated with LPS (final concentration of 0.5 μg / mL) for 24 h. The supernatant of the cells was added with Griess reagent for color development, mixed, incubated at room temperature for 10 min, and the absorbance was measured by A540. Calculation of IC of compounds for inhibiting LPS-induced NO production in RAW 264.7 50 value.
[0200] (2) Experimental results
[0201] Table 1: Inhibitory effect of compounds on LPS-induced NO secretion in RAW 264.7 cells
[0202]
[0203]
[0204] ND: Not Detected
[0205] According to Table 1, the compounds of the present invention have good inhibitory activity on LPS-induced NO secretion in RAW 264.7 cells.
[0206] 2. Effects of compounds on LPS-induced release of TNF-α, IL-6 and IL-1β from RAW 264.7 cells
[0207] (1) Experimental methods
[0208] After culturing RAW 264.7 cells at 37°C and 5% CO2 for 24 hours, the cells were incubated with the compound group of the present invention (for example, I-19 and I-24, the concentration was 0-20 μM) and the irinotecan group (the concentration was 0-100 μM) for 1 hour, and then replaced with DMEM medium (purchased from GIBCO, Invitrogen Corporation, NY, USA) containing LPS (final concentration was 1 mg / mL) and incubated for another 24 hours. After the incubation, the contents of TNF-α, IL-6 and IL-1β in the cell culture medium were detected by ELISA, and their IC 50value.
[0209] (2) Experimental results
[0210] Table 2: Inhibitory effects of compounds on the expression of TNF-α, IL-6 and IL-1β
[0211]
[0212] As shown in Table 2, the compounds of the present invention showed stronger inhibitory effects on TNF-α, IL-6 and IL-1β produced by RAW 264.7 induced by LPS than the positive control coixol.
[0213] In summary, the compounds of the present invention have good anti-inflammatory activity and show good research value and medicinal prospects.
Claims
1. Compound represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein X1 is selected from O or S; n is an integer between 1 and 4; Each R1 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, halogen; X2 is selected from C6-C 10 Aryl, or 5 to 10 membered heteroaryl, which is optionally substituted by one or more groups selected from the following: halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyl, cyano, nitro; m is 0 or 1; in, When m is 0, at least one R1 is a C1-C6 alkoxy group, and X2 is selected from It is optionally substituted by one or more groups selected from the group consisting of halogen, methyl, trifluoromethyl, methoxy, cyano.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2; Each R1 is independently selected from hydrogen, C1-C6 alkoxy, halogen; X2 is selected from C6-C 10 Aryl, or 5 to 10 membered heteroaryl, which is optionally substituted by one or more groups selected from the following: halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyl, cyano, nitro.
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein n is 1; R1 is selected from hydrogen, C1-C6 alkoxy, or halogen; X2 is selected from phenyl, or 5 to 10 membered heteroaryl, which is optionally substituted by one or more groups selected from the following: halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyl, cyano, nitro.
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein n is 1; R1 is selected from hydrogen, methoxy, or halogen; X2 is selected from phenyl, furanyl, thienyl, benzo[d][1,3]dioxole, benzofuranyl, pyridinyl, which is optionally substituted by one or more groups selected from the following: halogen, methyl, trifluoromethyl, methoxy, hydroxy, cyano, nitro.
5. The compound according to any one of claims 1 to 4, wherein the compound is a compound represented by formula (II): or a pharmaceutically acceptable salt thereof, wherein X1, X2, R1, and n are as defined in any one of claims 1 to 4.
6. The compound according to any one of claims 1 to 4, wherein the compound is a compound represented by formula (III): or a pharmaceutically acceptable salt thereof, wherein X1, X2, and R1 are as defined in any one of claims 1-4.
7. The compound according to claim 1, selected from: (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-phenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-fluorophenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-chlorophenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-methylphenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-trifluoromethylphenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-hydroxyphenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-methoxyphenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4-dimethoxyphenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-methoxyphenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3-methoxyphenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-chlorophenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3-chlorophenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(4-cyanophenyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-pyridyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(1,3-benzodiazol-5-yl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-thienyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-furyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3-furyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(5-methyl-2-furyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(5-bromo-2-furyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(1-benzofuran-2-yl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(5-nitro-2-furyl)acrylamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-2-benzofuranamide; (E)-N-(2-(6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-2-furanamide; (E)-N-(2-(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-furyl)acrylamide; (E)-N-(2-(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide; (E)-N-(2-(6-bromo-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(2-furyl)acrylamide; (E)-N-(2-(6-bromo-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide; or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising the compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
9. Use of the compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing and / or treating inflammation-related diseases.
10. The use according to claim 9, wherein the inflammation-related diseases include rheumatoid arthritis, gouty arthritis, osteoarthritis, spondylitis, systemic lupus erythematosus, psoriasis, eczema, subcutaneous inflammation, postpartum inflammation, enteritis, gastritis, inflammatory headache, periarteritis, allergic rhinitis, coronary plaque inflammation, inflammation caused by bacteria, inflammation caused by viruses, inflammation caused by surgery or gastric ulcer.
11. The use according to claim 9 or 10, wherein the inflammation-related disease is caused by excessive release or expression of NO, proinflammatory cytokines TNF-α, IL-1β, and / or IL-6.
